> top > docs > PMC:7276974 > annotations

PMC:7276974 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PMC-OGER-BB

Id Subject Object Predicate Lexical cue
T1 38-43 SP_6;NCBITaxon:9606 denotes human
T2 49-59 SP_7 denotes SARS-CoV-2
T3 73-79 UBERON:0001969 denotes plasma
T4 96-102 UBERON:0007023 denotes adults
T5 108-116 SP_7 denotes COVID-19
T6 268-273 SP_6;NCBITaxon:9606 denotes human
T7 279-289 SP_7 denotes SARS-CoV-2
T8 303-309 UBERON:0001969 denotes plasma
T9 326-332 UBERON:0007023 denotes adults
T10 345-355 SP_7 denotes SARS-CoV-2
T11 562-568 UBERON:0007023 denotes adults
T12 599-609 SP_7 denotes SARS-CoV-2
T13 635-649 UBERON:0001728 denotes nasopharyngeal
T14 653-666 UBERON:0001179 denotes oropharyngeal
T15 732-737 UBERON:0001443 denotes chest
T16 762-771 UBERON:0001982 denotes capillary
T17 1167-1172 NCBITaxon:10239 denotes viral
T18 1187-1198 NCBITaxon:11118 denotes coronavirus
T19 1213-1221 SP_7 denotes COVID-19
T20 1244-1249 NCBITaxon:10239 denotes viral
T21 1291-1301 SP_7 denotes SARS-CoV-2
T22 1321-1327 UBERON:0001969 denotes plasma
T23 1396-1407 GO:0015671 denotes oxygenation
T24 1443-1448 UBERON:0000062 denotes organ
T25 1502-1507 UBERON:0000178 denotes blood
T26 1546-1549 GO:0071735 denotes IgA
T27 1566-1575 GO:0007565 denotes pregnancy
T28 1653-1659 UBERON:0001969 denotes plasma
T29 1678-1688 DG_28 denotes remdesivir
T30 1706-1714 SP_7 denotes COVID-19
T31 1887-1897 SP_7 denotes SARS-CoV-2
T32 1898-1903 SP_6;NCBITaxon:9606 denotes human
T33 1917-1923 UBERON:0001969 denotes plasma
T34 1997-2005 SP_7 denotes COVID-19
T35 2059-2069 SP_7 denotes SARS-CoV-2
T36 2070-2078 GO:0042571 denotes antibody
T37 2199-2202 NCBITaxon:10376 denotes HBV
T38 2214-2218 NCBITaxon:10298 denotes HTLV
T39 2269-2277 SP_7 denotes COVID-19
T40 2332-2346 UBERON:0001728 denotes nasopharyngeal
T41 2372-2382 SP_7 denotes SARS-CoV-2
T42 2397-2403 UBERON:0001969 denotes Plasma
T43 2474-2479 UBERON:0000178 denotes Blood
T44 2584-2594 SP_7 denotes SARS-CoV-2
T45 2595-2601 UBERON:0001969 denotes plasma
T46 2667-2673 UBERON:0001969 denotes plasma
T47 2687-2693 UBERON:0001969 denotes plasma
T48 2732-2742 SP_7 denotes SARS-CoV-2
T49 2743-2751 GO:0042571 denotes antibody
T50 2807-2817 SP_7 denotes SARS-CoV-2
T51 2818-2826 GO:0042571 denotes antibody
T52 3529-3534 GO:0016265 denotes Death
T53 3748-3756 SP_7 denotes COVID-19
T54 3820-3829 CHEBI:31781;DG_23;CHEBI:31781 denotes lopinavir
T55 3831-3840 DG_30 denotes ritonavir
T56 3879-3887 SP_7 denotes COVID-19
T57 4045-4051 UBERON:0002405 denotes immune
T58 4052-4058 UBERON:0001969 denotes plasma
T59 4305-4315 SP_7 denotes SARS-CoV-2
T60 4316-4322 UBERON:0001969 denotes plasma
T61 4338-4344 UBERON:0001969 denotes plasma
T62 4681-4686 UBERON:0000178 denotes blood
T63 4859-4869 SP_7 denotes SARS-CoV-2

LitCovid-PD-FMA-UBERON

Id Subject Object Predicate Lexical cue fma_id
T1 73-79 Body_part denotes plasma http://purl.org/sig/ont/fma/fma62970
T2 303-309 Body_part denotes plasma http://purl.org/sig/ont/fma/fma62970
T3 732-737 Body_part denotes chest http://purl.org/sig/ont/fma/fma9576
T4 762-771 Body_part denotes capillary http://purl.org/sig/ont/fma/fma63194
T5 1321-1327 Body_part denotes plasma http://purl.org/sig/ont/fma/fma62970
T6 1443-1448 Body_part denotes organ http://purl.org/sig/ont/fma/fma67498
T7 1502-1507 Body_part denotes blood http://purl.org/sig/ont/fma/fma9670
T8 1546-1549 Body_part denotes IgA http://purl.org/sig/ont/fma/fma62874
T9 1653-1659 Body_part denotes plasma http://purl.org/sig/ont/fma/fma62970
T10 1917-1923 Body_part denotes plasma http://purl.org/sig/ont/fma/fma62970
T11 2070-2078 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T12 2194-2197 Body_part denotes HIV http://purl.org/sig/ont/fma/fma278683
T13 2397-2403 Body_part denotes Plasma http://purl.org/sig/ont/fma/fma62970
T14 2474-2479 Body_part denotes Blood http://purl.org/sig/ont/fma/fma9670
T15 2595-2601 Body_part denotes plasma http://purl.org/sig/ont/fma/fma62970
T16 2667-2673 Body_part denotes plasma http://purl.org/sig/ont/fma/fma62970
T17 2687-2693 Body_part denotes plasma http://purl.org/sig/ont/fma/fma62970
T18 2743-2751 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T19 2818-2826 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T20 4052-4058 Body_part denotes plasma http://purl.org/sig/ont/fma/fma62970
T21 4316-4322 Body_part denotes plasma http://purl.org/sig/ont/fma/fma62970
T22 4338-4344 Body_part denotes plasma http://purl.org/sig/ont/fma/fma62970
T23 4681-4686 Body_part denotes blood http://purl.org/sig/ont/fma/fma9670
T24 4870-4873 Body_part denotes arm http://purl.org/sig/ont/fma/fma24890
T25 4897-4900 Body_part denotes arm http://purl.org/sig/ont/fma/fma24890

LitCovid-PD-UBERON

Id Subject Object Predicate Lexical cue uberon_id
T1 732-737 Body_part denotes chest http://purl.obolibrary.org/obo/UBERON_0001443
T2 762-771 Body_part denotes capillary http://purl.obolibrary.org/obo/UBERON_0001982
T3 1443-1448 Body_part denotes organ http://purl.obolibrary.org/obo/UBERON_0000062
T4 1502-1507 Body_part denotes blood http://purl.obolibrary.org/obo/UBERON_0000178
T5 2474-2479 Body_part denotes Blood http://purl.obolibrary.org/obo/UBERON_0000178
T6 3115-3120 Body_part denotes scale http://purl.obolibrary.org/obo/UBERON_0002542
T7 3540-3545 Body_part denotes scale http://purl.obolibrary.org/obo/UBERON_0002542
T8 3911-3916 Body_part denotes scale http://purl.obolibrary.org/obo/UBERON_0002542
T9 4681-4686 Body_part denotes blood http://purl.obolibrary.org/obo/UBERON_0000178
T10 4870-4873 Body_part denotes arm http://purl.obolibrary.org/obo/UBERON_0001460
T11 4897-4900 Body_part denotes arm http://purl.obolibrary.org/obo/UBERON_0001460

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T1 49-57 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T2 108-116 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T3 279-287 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T4 345-353 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T5 356-365 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T6 599-607 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T7 610-619 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T8 1187-1211 Disease denotes coronavirus disease-2019 http://purl.obolibrary.org/obo/MONDO_0100096
T9 1213-1221 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T10 1291-1299 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T11 1437-1456 Disease denotes multi-organ failure http://purl.obolibrary.org/obo/MONDO_0043726
T12 1469-1487 Disease denotes allergic reactions http://purl.obolibrary.org/obo/MONDO_0000605|http://purl.obolibrary.org/obo/MONDO_0005271
T14 1469-1477 Disease denotes allergic http://purl.obolibrary.org/obo/MONDO_0004980
T15 1546-1560 Disease denotes IgA deficiency http://purl.obolibrary.org/obo/MONDO_0001341
T16 1706-1714 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T17 1887-1895 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T18 1997-2005 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T19 2059-2067 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T20 2177-2187 Disease denotes infections http://purl.obolibrary.org/obo/MONDO_0005550
T21 2269-2277 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T22 2372-2380 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T23 2584-2592 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T24 2732-2740 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T25 2807-2815 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T26 3748-3756 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T27 3879-3887 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T28 3982-3991 Disease denotes influenza http://purl.obolibrary.org/obo/MONDO_0005812
T29 4305-4313 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T30 4859-4867 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T1 38-43 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes human
T2 73-79 http://purl.obolibrary.org/obo/UBERON_0001969 denotes plasma
T3 118-119 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T4 142-143 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T5 163-164 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T6 193-203 http://purl.obolibrary.org/obo/BFO_0000030 denotes Objectives
T7 208-211 http://purl.obolibrary.org/obo/PR_000001343 denotes aim
T8 268-273 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes human
T9 303-309 http://purl.obolibrary.org/obo/UBERON_0001969 denotes plasma
T10 388-389 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T11 572-574 http://purl.obolibrary.org/obo/CLO_0050510 denotes 18
T12 627-631 http://purl.obolibrary.org/obo/UBERON_0000473 denotes test
T13 732-737 http://www.ebi.ac.uk/efo/EFO_0000965 denotes chest
T14 799-801 http://purl.obolibrary.org/obo/CLO_0001527 denotes 94
T15 1036-1037 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T16 1274-1282 http://purl.obolibrary.org/obo/CLO_0001658 denotes activity
T17 1321-1327 http://purl.obolibrary.org/obo/UBERON_0001969 denotes plasma
T18 1387-1395 http://purl.obolibrary.org/obo/UBERON_0000158 denotes membrane
T19 1443-1448 http://purl.obolibrary.org/obo/UBERON_0003103 denotes organ
T20 1502-1507 http://purl.obolibrary.org/obo/UBERON_0000178 denotes blood
T21 1502-1507 http://www.ebi.ac.uk/efo/EFO_0000296 denotes blood
T22 1526-1529 http://purl.obolibrary.org/obo/CL_0000990 denotes CDC
T23 1653-1659 http://purl.obolibrary.org/obo/UBERON_0001969 denotes plasma
T24 1898-1903 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes human
T25 1917-1923 http://purl.obolibrary.org/obo/UBERON_0001969 denotes plasma
T26 2019-2026 http://purl.obolibrary.org/obo/UBERON_0000473 denotes testing
T27 2102-2103 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T28 2330-2331 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T29 2397-2403 http://purl.obolibrary.org/obo/UBERON_0001969 denotes Plasma
T30 2474-2479 http://purl.obolibrary.org/obo/UBERON_0000178 denotes Blood
T31 2474-2479 http://www.ebi.ac.uk/efo/EFO_0000296 denotes Blood
T32 2529-2534 http://purl.obolibrary.org/obo/CLO_0053711 denotes a 2:1
T33 2595-2601 http://purl.obolibrary.org/obo/UBERON_0001969 denotes plasma
T34 2667-2673 http://purl.obolibrary.org/obo/UBERON_0001969 denotes plasma
T35 2687-2693 http://purl.obolibrary.org/obo/UBERON_0001969 denotes plasma
T36 2704-2710 http://purl.obolibrary.org/obo/UBERON_0000473 denotes tested
T37 2790-2796 http://purl.obolibrary.org/obo/UBERON_0000473 denotes tested
T38 2862-2863 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T39 3192-3202 http://purl.obolibrary.org/obo/CLO_0001658 denotes activities
T40 3252-3262 http://purl.obolibrary.org/obo/CLO_0001658 denotes activities
T41 3643-3655 http://purl.obolibrary.org/obo/OBI_0000245 denotes Organization
T42 3758-3759 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T43 3893-3894 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T44 4003-4004 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T45 4026-4027 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T46 4052-4058 http://purl.obolibrary.org/obo/UBERON_0001969 denotes plasma
T47 4277-4282 http://purl.obolibrary.org/obo/CLO_0053711 denotes a 2:1
T48 4316-4322 http://purl.obolibrary.org/obo/UBERON_0001969 denotes plasma
T49 4338-4344 http://purl.obolibrary.org/obo/UBERON_0001969 denotes plasma
T50 4351-4352 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T51 4681-4686 http://purl.obolibrary.org/obo/UBERON_0000178 denotes blood
T52 4681-4686 http://www.ebi.ac.uk/efo/EFO_0000296 denotes blood
T53 4870-4873 http://www.ebi.ac.uk/efo/EFO_0001410 denotes arm
T54 4897-4900 http://www.ebi.ac.uk/efo/EFO_0001410 denotes arm
T55 5019-5020 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T56 5036-5040 http://purl.obolibrary.org/obo/UBERON_0000473 denotes test
T57 5113-5114 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T58 5588-5591 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T59 5631-5632 http://purl.obolibrary.org/obo/CLO_0001020 denotes a

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T1 772-778 Chemical denotes oxygen http://purl.obolibrary.org/obo/CHEBI_25805
T2 845-851 Chemical denotes oxygen http://purl.obolibrary.org/obo/CHEBI_25805
T3 1162-1178 Chemical denotes anti-viral agent http://purl.obolibrary.org/obo/CHEBI_22587
T4 1239-1255 Chemical denotes anti-viral agent http://purl.obolibrary.org/obo/CHEBI_22587
T5 1678-1688 Chemical denotes remdesivir http://purl.obolibrary.org/obo/CHEBI_145994
T6 2221-2223 Chemical denotes II http://purl.obolibrary.org/obo/CHEBI_74067
T7 3307-3313 Chemical denotes oxygen http://purl.obolibrary.org/obo/CHEBI_25805
T8 3354-3360 Chemical denotes oxygen http://purl.obolibrary.org/obo/CHEBI_25805
T9 3398-3404 Chemical denotes oxygen http://purl.obolibrary.org/obo/CHEBI_25805
T10 3820-3829 Chemical denotes lopinavir http://purl.obolibrary.org/obo/CHEBI_31781
T11 3831-3840 Chemical denotes ritonavir http://purl.obolibrary.org/obo/CHEBI_45409
T12 4659-4664 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T13 4746-4751 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T14 5614-5620 Chemical denotes Letter http://purl.obolibrary.org/obo/CHEBI_6446

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T1 0-117 Sentence denotes Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19:
T2 118-192 Sentence denotes A structured summary of a study protocol for a randomized controlled trial
T3 193-203 Sentence denotes Objectives
T4 204-366 Sentence denotes The aim of this study is to evaluate the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in hospitalized adults with severe SARS-CoV-2 infection.
T5 367-379 Sentence denotes Trial Design
T6 380-518 Sentence denotes This is a prospective, single-center, phase 2, randomized, controlled trial that is blinded to participants and clinical outcome assessor.
T7 519-531 Sentence denotes Participants
T8 532-1091 Sentence denotes Eligible participants include adults (≥ 18 years) with evidence of SARS-CoV-2 infection by PCR test of nasopharyngeal or oropharyngeal swab within 14 days of randomization, evidence of infiltrates on chest radiography, peripheral capillary oxygen saturation (SpO2) ≤ 94% on room air, and/or need for supplemental oxygen, non-invasive mechanical ventilation, or invasive mechanical ventilation, who are willing and able to provide written informed consent prior to performing study procedures or who have a legally authorized representative available to do so.
T9 1092-1576 Sentence denotes Exclusion criteria include participation in another clinical trial of anti-viral agent(s)* for coronavirus disease-2019 (COVID-19), receipt of any anti-viral agent(s)* with possible activity against SARS-CoV-2 <24 hours prior to plasma infusion, mechanical ventilation (including extracorporeal membrane oxygenation [ECMO]) for ≥ 5 days, severe multi-organ failure, history of allergic reactions to transfused blood products per NHSN/CDC criteria, known IgA deficiency, and pregnancy.
T10 1577-1669 Sentence denotes Included participants will be hospitalized at the time of randomization and plasma infusion.
T11 1670-1728 Sentence denotes *Use of remdesivir as treatment for COVID-19 is permitted.
T12 1729-1820 Sentence denotes The study will be undertaken at Columbia University Irving Medical Center in New York, USA.
T13 1821-1848 Sentence denotes Intervention and comparator
T14 1849-1924 Sentence denotes The investigational treatment is anti-SARS-CoV-2 human convalescent plasma.
T15 1925-2119 Sentence denotes To procure the investigational treatment, volunteers who recovered from COVID-19 will undergo testing to confirm the presence of anti-SARS-CoV-2 antibody to the spike trimer at a 1:400 dilution.
T16 2120-2241 Sentence denotes Donors will also be screened for transfusion-transmitted infections (e.g. HIV, HBV, HCV, WNV, HTLV-I/II, T. cruzi, ZIKV).
T17 2242-2396 Sentence denotes If donors have experienced COVID-19 symptoms within 28 days, they will be screened with a nasopharyngeal swab to confirm they are SARS-CoV-2 PCR-negative.
T18 2397-2487 Sentence denotes Plasma will be collected using standard apheresis technology by the New York Blood Center.
T19 2488-2674 Sentence denotes Study participants will be randomized in a 2:1 ratio to receive one unit (200 – 250 mL) of anti-SARS-CoV-2 plasma versus one unit (200 – 250 mL) of the earliest available control plasma.
T20 2675-2900 Sentence denotes The control plasma cannot be tested for presence of anti-SARS-CoV-2 antibody prior to the transfusion, but will be tested for anti- SARS-CoV-2 antibody after the transfusion to allow for a retrospective per-protocol analysis.
T21 2901-2914 Sentence denotes Main outcomes
T22 2915-2968 Sentence denotes The primary endpoint is time to clinical improvement.
T23 2969-3145 Sentence denotes This is defined as time from randomization to either discharge from the hospital or improvement by one point on the following seven-point ordinal scale, whichever occurs first.
T24 3146-3148 Sentence denotes 1.
T25 3149-3202 Sentence denotes Not hospitalized with resumption of normal activities
T26 3203-3205 Sentence denotes 2.
T27 3206-3262 Sentence denotes Not hospitalized, but unable to resume normal activities
T28 3263-3265 Sentence denotes 3.
T29 3266-3313 Sentence denotes Hospitalized, not requiring supplemental oxygen
T30 3314-3316 Sentence denotes 4.
T31 3317-3360 Sentence denotes Hospitalized, requiring supplemental oxygen
T32 3361-3363 Sentence denotes 5.
T33 3364-3451 Sentence denotes Hospitalized, requiring high-flow oxygen therapy or non-invasive mechanical ventilation
T34 3452-3454 Sentence denotes 6.
T35 3455-3525 Sentence denotes Hospitalized, requiring ECMO, invasive mechanical ventilation, or both
T36 3526-3528 Sentence denotes 7.
T37 3529-3534 Sentence denotes Death
T38 3535-3757 Sentence denotes This scale, designed to assess clinical status over time, was based on that recommended by the World Health Organization for use in determining efficacy end-points in clinical trials in hospitalized patients with COVID-19.
T39 3758-4059 Sentence denotes A recent clinical trial evaluating the efficacy and safety of lopinavir- ritonavir for patients hospitalized with severe COVID-19 used a similar ordinal scale, as have recent clinical trials of novel therapeutics for severe influenza, including a post-hoc analysis of a trial evaluating immune plasma.
T40 4060-4221 Sentence denotes The primary safety endpoints are cumulative incidence of grade 3 and 4 adverse events and cumulative incidence of serious adverse events during the study period.
T41 4222-4235 Sentence denotes Randomization
T42 4236-4386 Sentence denotes Study participants will be randomized in a 2:1 ratio to receive anti-SARS-CoV-2 plasma versus control plasma using a web-based randomization platform.
T43 4387-4536 Sentence denotes Treatment assignments will be generated using randomly permuted blocks of different sizes to minimize imbalance while also minimizing predictability.
T44 4537-4555 Sentence denotes Blinding (masking)
T45 4556-4676 Sentence denotes The study participants and the clinicians who will evaluate post-treatment outcomes will be blinded to group assignment.
T46 4677-4763 Sentence denotes The blood bank and the clinical research team will not be blinded to group assignment.
T47 4764-4802 Sentence denotes Numbers to be randomized (sample size)
T48 4803-4901 Sentence denotes We plan to enroll 129 participants, with 86 in the anti-SARS-CoV-2 arm, and 43 in the control arm.
T49 4902-4985 Sentence denotes Among the participants, we expect ~70% or n = 72 will achieve clinical improvement.
T50 4986-5135 Sentence denotes This will yield an 80% power for a one-sided Wald test at 0.15 level of significance under the proportional hazards model with a hazard ratio of 1.5.
T51 5136-5148 Sentence denotes Trial Status
T52 5149-5196 Sentence denotes Protocol AAAS9924, Version 17APR2020, 4/17/2020
T53 5197-5218 Sentence denotes Start of recruitment:
T54 5219-5233 Sentence denotes April 20, 2020
T55 5234-5257 Sentence denotes Recruitment is ongoing.
T56 5258-5276 Sentence denotes Trial registration
T57 5277-5308 Sentence denotes ClinicalTrials.gov: NCT04359810
T58 5309-5336 Sentence denotes Date of trial registration:
T59 5337-5351 Sentence denotes April 24, 2020
T60 5352-5378 Sentence denotes Retrospectively registered
T61 5379-5392 Sentence denotes Full protocol
T62 5393-5501 Sentence denotes The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1).
T63 5502-5682 Sentence denotes In the interest of expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.

LitCovid-PD-HP

Id Subject Object Predicate Lexical cue hp_id
T1 338-365 Phenotype denotes severe SARS-CoV-2 infection http://purl.obolibrary.org/obo/HP_0033141
T2 1546-1560 Phenotype denotes IgA deficiency http://purl.obolibrary.org/obo/HP_0002720

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
3 38-43 Species denotes human Tax:9606
4 49-59 Species denotes SARS-CoV-2 Tax:2697049
5 108-116 Disease denotes COVID-19 MESH:C000657245
9 268-273 Species denotes human Tax:9606
10 279-289 Species denotes SARS-CoV-2 Tax:2697049
11 345-365 Disease denotes SARS-CoV-2 infection MESH:C000657245
13 475-487 Species denotes participants Tax:9606
25 541-553 Species denotes participants Tax:9606
26 1291-1301 Species denotes SARS-CoV-2 Tax:2697049
27 1586-1598 Species denotes participants Tax:9606
28 772-778 Chemical denotes oxygen MESH:D010100
29 845-851 Chemical denotes oxygen MESH:D010100
30 599-619 Disease denotes SARS-CoV-2 infection MESH:C000657245
31 1187-1211 Disease denotes coronavirus disease-2019 MESH:C000657245
32 1213-1221 Disease denotes COVID-19 MESH:C000657245
33 1437-1456 Disease denotes multi-organ failure MESH:D009102
34 1469-1487 Disease denotes allergic reactions MESH:D004342
35 1546-1560 Disease denotes IgA deficiency MESH:D017098
38 1678-1688 Chemical denotes remdesivir MESH:C000606551
39 1706-1714 Disease denotes COVID-19 MESH:C000657245
56 2214-2223 Gene denotes HTLV-I/II
57 2086-2091 Gene denotes spike Gene:43740568
58 1898-1903 Species denotes human Tax:9606
59 2225-2233 Species denotes T. cruzi Tax:5693
60 2235-2239 Species denotes ZIKV Tax:64320
61 2372-2382 Species denotes SARS-CoV-2 Tax:2697049
62 2494-2506 Species denotes participants Tax:9606
63 1887-1897 Species denotes SARS-CoV-2 Tax:2697049
64 2059-2069 Species denotes SARS-CoV-2 Tax:2697049
65 2584-2594 Species denotes SARS-CoV-2 Tax:2697049
66 2732-2742 Species denotes SARS-CoV-2 Tax:2697049
67 2807-2817 Species denotes SARS-CoV-2 Tax:2697049
68 1997-2005 Disease denotes COVID-19 MESH:C000657245
69 2177-2187 Disease denotes infections MESH:D007239
70 2194-2197 Disease denotes HIV MESH:D015658
71 2269-2277 Disease denotes COVID-19 MESH:C000657245
73 3307-3313 Chemical denotes oxygen MESH:D010100
75 3354-3360 Chemical denotes oxygen MESH:D010100
77 3398-3404 Chemical denotes oxygen MESH:D010100
79 3529-3534 Disease denotes Death MESH:D003643
85 3734-3742 Species denotes patients Tax:9606
86 3845-3853 Species denotes patients Tax:9606
87 3820-3840 Chemical denotes lopinavir- ritonavir MESH:C558899
88 3748-3756 Disease denotes COVID-19 MESH:C000657245
89 3879-3887 Disease denotes COVID-19 MESH:C000657245
92 4242-4254 Species denotes participants Tax:9606
93 4305-4315 Species denotes SARS-CoV-2 Tax:2697049
95 4566-4578 Species denotes participants Tax:9606
99 4825-4837 Species denotes participants Tax:9606
100 4912-4924 Species denotes participants Tax:9606
101 4859-4869 Species denotes SARS-CoV-2 Tax:2697049